Skip to main content
Advicenne logo

Advicenne — Investor Relations & Filings

Ticker · ALDVI ISIN · FR0013296746 LEI · 969500YT5VMEYAYODW34 PA Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2019-08-29 Regulatory Filings
Country FR France
Listing PA ALDVI

About Advicenne

https://advicenne.com

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing treatments for rare renal diseases. The company focuses on addressing unmet medical needs in nephrology for both children and adults. Its lead product, Sibnayal®, is an approved treatment for distal Renal Tubular Acidosis (dRTA). Advicenne is committed to improving the lives of patients with rare kidney conditions by developing therapeutics, including pediatric-friendly formulations, suitable for patients of all ages.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated August 29, 2019, announcing a significant operational milestone: the inclusion of the first patient in the Phase III clinical trial (ARENA-2) for their drug candidate ADV7103 in the US for treating Distal Renal Tubular Acidosis (dRTA). This type of announcement, detailing clinical trial progress, regulatory milestones (like Orphan Drug Designation application), and future commercial expectations, is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on operational progress and clinical trial initiation rather than comprehensive financial results (which would be an ER or IR), and it is not a transcript, presentation, or formal regulatory filing like a 10-K, it best fits the 'Earnings Release' category, which often includes key operational highlights preceding formal financial reports. Given the focus on a major clinical trial update, ER is the most appropriate fit among the options provided for a major corporate announcement.
2019-08-29 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly cites French regulatory articles (Code commerce and AMF General Regulation) and provides a table detailing the number of shares and voting rights as of July 31, 2019. This content directly relates to reporting changes in the total number of shares and voting rights, which is a specific regulatory disclosure. Among the provided definitions, none perfectly match a 'Monthly Voting Rights Disclosure'. However, this type of disclosure is a fundamental regulatory filing. It is not an AGM, 10-K, ER, or IR. It is a specific regulatory update. Given the options, 'RNS' (Regulatory Filings - general/miscellaneous) is the most appropriate fallback for a specific, non-standard regulatory disclosure that doesn't fit the other categories like Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since it is a direct regulatory disclosure, RNS is the best fit as a general regulatory filing category.
2019-08-27 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly cites French regulations (Code commerce and AMF General Regulation) and provides a table detailing the number of shares and the total gross and net voting rights as of June 30, 2019. This type of mandatory periodic disclosure regarding the total share capital and voting rights structure is a specific regulatory filing requirement, often related to capital structure changes or mandatory updates. While it relates to capital, it is not a general financing announcement (CAP) or a share issue/repurchase (SHA/POS). It is a specific regulatory disclosure about the capital structure's voting power. Given the options, this fits best under a general Regulatory Filing (RNS) or potentially a Share Issue/Capital Change (SHA) if the context implies a change, but since it's a routine monthly update on the *total* rights, RNS is the most appropriate general regulatory category for mandatory, non-standard reports, or it could be considered a specific type of capital disclosure. However, since the core content is the official count of voting rights as mandated by the AMF, and there isn't a specific code for 'Voting Rights Disclosure', RNS serves as the best fit for a mandatory regulatory update that isn't a full financial report or a specific transaction notice. Given the nature of the data (total voting rights), it is a specific regulatory disclosure.
2019-07-29 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is titled "Bilan semestriel du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont" (Semi-annual balance sheet of the liquidity contract concluded with Gilbert Dupont Stock Brokerage Firm). It details the status of a liquidity contract (share count and cash balance) as of June 28, 2019, and reports on trading activity during the first half of 2019 (1e semestre 2019). This type of regular reporting on liquidity management, often mandated by stock exchanges, is a specific financial disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR) which focuses on comprehensive financial statements. Since it specifically details the status of a liquidity contract, it relates to capital management and market operations. Given the options, 'Capital/Financing Update' (CAP) is the closest fit as liquidity contracts are financing/capital structure tools, although 'Regulatory Filings' (RNS) is a possibility if this is a mandatory, non-standard filing. However, the content is highly specific to the liquidity agreement, which falls under the broader umbrella of capital maintenance/financing activities. Since there is no specific code for 'Liquidity Contract Report', CAP is the most appropriate classification among the provided choices for a report detailing capital/financing arrangements.
2019-07-29 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a press release dated July 26, 2019, announcing that Advicenne will present at the Solebury Trout European Biotech Investor Day in NYC on August 1st, 2019. It details the company's progress, lead drug candidate (ADV7103), and includes standard forward-looking statements and contact information typical of corporate news releases. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about an upcoming investor event, which falls under general corporate communications. Since there is no specific category for 'Investor Event Announcement,' and it is a general corporate update/announcement, the most appropriate fallback category is Regulatory Filings (RNS), as it is a public disclosure that doesn't fit the more specific financial or governance categories. However, given the context of presenting at an investor day, it is a form of investor relations communication. Reviewing the definitions, none perfectly capture an 'Investor Presentation Announcement' unless the presentation itself was attached (which would lean towards IP or RPA). Since this is an announcement *about* presenting, and it's a general corporate update, RNS is the best fit among the provided options as a general regulatory/corporate announcement.
2019-07-26 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated July 26, 2019, announcing that Advicenne's CEO and CFO will present at the 'Solebury Trout European Biotech Investor Day' in New York on August 1, 2019. This announcement details participation in an external investor event where company progress and outlook will be discussed. This type of communication, which announces management's participation in an investor conference or presentation, is best classified as an Investor Presentation (IP) or a related announcement, as it is designed to convey information directly to investors about the company's status and strategy, often mirroring content that would be in a formal presentation. Since the document itself is the announcement of the presentation rather than the presentation slides or a transcript of the Q&A, and it focuses on management presenting key updates, 'Investor Presentation' (IP) is the most fitting category, as it relates directly to investor outreach activities.
2019-07-26 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.